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Substantial evidence now supports the view that epigenetic changes have a role in the development of human prostate cancer.
Analyses of the patterns of epigenetic alteration are providing important insights into the origin of this disease and have identified
specific alterations that may serve as useful diagnostic and prognostic biomarkers. Examination of cancer methylation patterns
supports a stem cell origin of prostate cancer. It is well established that methylation of GSTpi is a marker of prostate cancer, and global
patterns of histone marking appear to be linked to cancer prognosis with levels of acetylated histones H3K9, H3K18, and H4K12, and
of dimethylated H4R3 and H3K4, dividing low-grade prostate cancer (Gleason 6 or less) into two prognostically separate groups.
Elevated levels of several components of the polycomb group protein complex, EZH2, BMI1, and RING1, can also act as biomarkers
of poor clinical outcome. Many components of the epigenetic machinery, including histone deacetylase (whose expression level is
linked to the TMPRSS2:ERG translocation) and the histone methylase EZH2, are potential therapeutic targets. The recent discovery of
the role of small RNAs in governing the epigenetic status of individual genes offers exciting new possibilities in therapeutics and
chemoprevention.
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The term ‘epigenetic’ refers to mechanisms of inherited change of
gene expression that do not involve changes in DNA sequence or
copy number. Conventionally, this includes CpG methylation,
histone modification or marking, and gene imprinting, but recent
evidence shows that small RNAs could also play a critical role in
directing epigenetic silencing. In cancers, when alterations in the
normal epigenetic portrait arise, they are subjected to the same
selective pressures as genetic alterations. However, epigenetic
alterations have the potential to cause changes in the expression of
individual or groups of genes at considerably elevated rates when
compared with their genetic counterparts. A view is emerging that
epigenetic disruption of progenitor cells may be an initial step in
cancer development, leading to a polyclonal precursor population
within which subsequent genetic and epigenetic events may occur.
There is considerable interplay between different classes of
epigenetic modification, but the mechanisms of interaction are
poorly understood, and the hierarchical order of epigenetic
alterations during unscheduled gene silencing in cancer is
unknown. Here, following a summary of the evidence supporting
the role of epigenetic change in prostate cancer development, we
review new concepts and technologies emerging in this field that
may have particular relevance to the clinical management of
prostate cancer.
EPIGENETIC CHANGES IN PROSTATE CANCER
DNA methylation
The link between methylation at the N5-position of cytosine in
CpG sequences and cancer development is well established. Cancer
formation is accompanied by dramatic changes in the cellular
methylation profile such that global demethylation of the genome
occurs in parallel with CpG hypermethylation at specific genes
strongly linked to their transcriptional inactivation. A list of genes
that are hypermethylated at CpG islands in prostate cancer is
shown in Table 1. Many of these genes, including INK4a, RASSF1a
and APC, exhibit tumour suppressor functions whose inactivation
associated with hypermethylation of CpG islands in 50 regulatory
regions occurs during cancer development. Inappropriate gene
hypermethylation catalysed by DNA methylases (DNMTs) may
represent an early event in cancer development, possibly linked to
ageing. Methylation of GSTpi was absent in normal epithelium and
present in 6.4% of proliferative inflammatory atrophy, in 70% of
high-grade PIN and in 90% of prostate cancer (Nakayama et al,
2003). When methylation at the APC gene was considered together
with methylation of GSTpi, the sensitivity for detecting cancer
approached 100% (Jeronimo et al, 2004). Methylation may also be
associated with tumour progression. For example, CpG hyper-
methylation of the cell adhesion gene E-cadherin in breast and
prostate is integral to epithelial-to-mesenchymal transition that is
believed to play a prominent role in tumour progression
(Lombaerts et al, 2006). Methylation of the oestrogen receptor
alpha (ESR1) gene, whose downregulation has been suggested to
play a role in cancer metastasis, has also been documented in
prostate cancer (Li et al, 2004). Hypomethylation of specific genes
is also linked to prostate cancer development. For example, Wang
Received 22 January 2008; revised 16 September 2008; accepted 15
October 2008; published online 11 November 2008
*Correspondence: Professor CS Cooper;
E-mail: colin.cooper@icr.ac.uk
British Journal of Cancer (2009) 100, 240 – 245
& 2009 Cancer Research UK All rights reserved 0007 – 0920/09 $32.00
www.bjcancer.com
et al (2007) have reported hypomethylation of WNT5A, CRIP1, and
S100P in cancer but not in normal prostate. Interestingly, CpG
methylation status appeared to control binding of MYB to the
WNT5A promoter region.
Histone marking
Histone alterations by methylation, acetylation, and ubiquitination
(called ‘marks’) are inherited as epigenetic variations and linked
to gene activation or silencing depending on the precise nature
and position of the modification (called the histone code).
Promoters of expressed genes are commonly associated with the
active marks, such as H3 lysine 4 dimethylation (H3K4me2) and
H3 lysine 9 acetylation (H3K9acetyl). In contrast, in transcription-
ally silenced genes, these are replaced by repressive marks,
including H3K27me3, H3K9me2, and H3K9me3. Changes in
histone marks arise during cancer development and appear to
have prognostic potential. Fraga et al (2005a) found that loss of
monoacetylated lysine 16 and trimethylated lysine 20 forms of
histone H4 is a global hallmark of human cancers, and in prostate
cancer, global patterns of histone modification are linked to the
risk of prostate cancer recurrence (Seligson et al, 2005).
Particularly, the levels of acetylated histones at H3K9, H3K18,
and H4K12, and of dimethylated H4R3 and H3K4, divided low-
grade prostate cancer (Gleason 6 or less) into two prognostically
separate groups.
Polycomb group (PcG) protein complexes PRC1–PRC4 play a
key role in controlling transcriptional silencing. Polycomb group
protein complex-1 contains BMI1 and RING1, whereas PRC2–
PRC4 contain EZH2. Expression of all three proteins (BMI1,
RING1, and EZH2) is associated with adverse pathological features
in prostate cancer, but only BMI1 provides additional prognostic
power in multivariate analysis. EZH2 is the component of the
PRC2 complex responsible for catalysing methylation of both
H3K27 and H1K26, but this protein can also become associated
with DNMTs, and has a role in the induction and targeting of DNA
methylation. Following the action of EZH2, the H3K27me3 mark
attracts PRC1, which contains other proteins, including BMI1,
which is involved in maintaining gene silencing. One of the target
genes for EZH2 in prostate cancer cells is DAB2IP (Chen et al,
2005), whose encoded protein is a potent cell growth inhibitor and
modulator of Ras-signalling. Overexpressed EZH2 becomes
associated with the DAB2IP promoter and appears to facilitate
recruitment of other components of EZH2 complex (Chen et al,
2005). These alterations are linked to increased levels of
H3K27me2 and H3K27me3 and of histone deacetylase (HDAC)-1
associated with the promoter. The MSMB gene, which encodes the
inhibitor of prostate cancer development PSP94, appears to be
similarly targeted by EZH2 (Beke et al, 2007).
Formation of acetyl histone marks that are associated with
transcriptional activation, is catalysed by histone acetyl trans-
ferases (HATs). In leukaemia, the HAT TIP60 directly interacts
with, and is a co-activator for, the translocation activated
transcription factor C/EBPa. The co-activator function is acetyl-
transferase dependent, with acetylation of histones 3 and 4
associated with activation of downstream genes. Histone acetyl
transferases involved in histone marking may also acetylate non-
histone proteins, although the relationship of these activities to
epigenetic marking is unclear. For example, treatment of prostate
cancers with di-hydrotestosterone induces acetylation at a lysine
residue in the hinge region of the androgen receptor (AR) by the
HATs p300, P/CAF, and TIP60. Acetylation enhances transactiva-
tion of the AR by coactivators (SRC1, Ubc9, and ARA70) and
increases access to androgen-responsive elements. Similarly, TIP60
also has a role in modulating DNA repair: TIP60 acetylates p53,
and activation of the DNA damage sensor ATM depends on TIP60.
Haploinsufficiency of TIP60 has been linked to breast cancer
development (Gorrini et al, 2007) and it would be interesting to see
whether alterations in TIP60 are also important in the develop-
ment of prostate cancer.
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Acetyl groups are removed from both histone and non-histone
proteins by HDACs. The HDAC1 gene has been identified as a gene
overexpressed in prostate cancers containing the TMPRSS2–ERG
fusion (Iljin et al, 2006), with its highest levels found in hormone
refractory disease. Another HDAC, SirT1, plays a role in
transcriptional silencing of DNA hypermethylated cancer genes
by localising to the gene promoters to deacetylate H4K16 and
H3K9. Downregulation of SirT1 activity results in reactivation of
silenced Wnt agonist genes (the SFRPs) and hence dampens
signalling through the activated Wnt pathway in colon and breast
cancer cells (Pruitt et al, 2006). These studies may also have
relevance to prostate cancer where the Wnt pathway is known to
be activated in a proportion of cases.
The relationship between DNA hypermethylation and
polycomb-based histone modification appears complex. The
conventional view (e.g., see discussion of ‘stem-cell-ness’ below)
is that inactive histone marks are associated with DNA hyper-
methylated promoters, whereas active marks are normally
associated with hypomethylated promoters. Recent data from
Kondo et al (2008) challenge this view. Using a ChIP-based
microarray approach, they found that in cancer around 5% of
promoters (16% CpG, 84% non-CpG) were enriched with
repressive mark H3K27me3. The genes containing this mark were
specifically silenced in prostate cancer compared with normal
tissue even though genes with CpG islands only showed low levels
of DNA methylation. Downregulation of EZH2 and inhibition of
deacetylases restored gene expression without altering promoter
DNA methylation. This independence of DNA-methylation and
histone marking appeared to conflict with previous studies but
could be explained by tissue and cancer-specific mechanisms.
Future studies will need to address why DNA methylation in
cancer affects some silenced PcG targets but not others.
Loss of imprinting
Imprinting is a process that allows specific expression from either
the maternal or the paternal allele. Evidence suggesting a role for
loss of imprinting in cancer development initially came from
reports that loss of heterozygosity at the 11p15 locus in Wilms
tumours invariably involved loss of the maternal allele and
duplication of the paternal allele (Kurukuti et al, 2006). This
chromosome region is now known to contain the reciprocally
imprinted and adjacent IGF-II and H19 alleles. These observations
may be of particular relevance to prostate cancer because
alterations both of insulin-like growth factors (IGFs) and of their
binding proteins (IGFBPs) have been implicated in development of
this disease. Biallelic expression of IGF-II, implying reactivation of
the maternal allele, was observed in prostate cancers removed at
radical surgery for localised adenocarcinoma as well as in samples
of apparently normal adjacent tissue. In contrast, biallelic
expression was absent from virtually all BPH specimens (Jarrard
et al, 1995). DNA methylation of the imprinted suppressor gene
p57/Kip2 that encodes an embryonic cyclin-dependant kinase has
also been found in a high proportion (56%) of prostate cancer
(Lodygin et al, 2005).
A key question is whether the different classes of epigenetic
changes discussed above are responsible for driving cancer
development, or whether some of the alterations are a secondary
consequence of the development of this disease. If the former is
true, defects in the machinery controlling DNA-methylation and
chromatin structure should be linked to cancer. This is indeed the
case, although current supporting evidence is entirely restricted to
cancer types other than prostate. It is not our intention to carry out
a systematic review of this area apart from noting that mutations
linked to cancer development in humans or mice have been found
in genes encoding DNA methyltransferases, methyl-CpG-binding
proteins, chromatin remodelling proteins (SNF5, ATRX), histone
methyltransferase (SUV39H), histone acetylases (MOZ, MORF),
and histone deacetylases (HDAC2).
RNA-MEDIATED TRANSCRIPTIONAL SILENCING
Small RNAs may have a key role in controlling the epigenetic state.
It is well established that siRNAs can direct post-transcriptional
silencing, but it is now becoming apparent that promoter-targeted
siRNAs can also direct both the activation and repression of
gene transcription through orchestrating epigenetic changes in a
process that requires RNA polymerase II and Argonaute 1 and 2.
The targeted promoter may be rendered transcriptionally silent,
exhibiting the repressing marks H3K9me2 and H3K27me3 (Morris,
2008). Han et al (2007) provided evidence that a low-abundance
mRNA containing an extended 50-untranslated region that over-
laps the gene promoter is required for RNA-directed epigenetic
modifications. In their model, the low-copy-number RNAs
transcribed by RNA polymerase II from the promoter region are
recognised by an antisense siRNA, and function as a recognition
motif to direct epigenetic silencing complexes to the correspond-
ing target promoters. Human cells express many endogenous
species of small RNAs, including endogenous siRNAs, that are
candidates for involvement in this process. It is now important to
establish whether this model represents a general mechanism of
endogenous epigenetic control, and whether appropriately targeted
siRNA can be used to permanently silence individual genes (e.g.,
the TMRSS2 –ERG gene fusion) in novel therapeutic and
chemopreventive approaches.
STEM CELL-NESS IN CANCER DEVELOPMENT
A popular view is that cancer stem cells or dividing precursor cells
are the point of origin of individual cancers. In support of this
hypothesis, cancers often exhibit alteration in pathways known to
be involved in the preservation of stem cells. New evidence
indicates that particular chromatin patterns controlling important
regulatory genes in stem cells may leave these same genes
vulnerable to DNA methylation during cancer development.
Ohm et al (2007) compiled a set of 29 genes with tumour-
suppressing potential that were frequently silenced by hyper-
methylation in cancer cells, including 16 that are hypermethylated
in prostate cancer (Table 1). The authors found that these genes
were usually unmethylated in both normal and malignant
embryonic cells, but noted that most of these genes occurred
within a subset (B10% of all genes) associated with PcG in stem
cells. Further analysis showed that, in embryonic stem (ES) cells,
these genes are held in a ‘bivalent’ transcription-ready state by a
promoter chromatin pattern consisting of the repressive mark
histone H3K27me3 produced by PcG proteins, including SUZ12,
EZH2, and SirT1, and by the active mark H3K4me2 (Figure 1). In
embryonic carcinoma cells, two additional repressive marks,
dimethylated H3K9 and trimethylated H3K9, which are each
associated with DNA hypermethylation in adult cancers, were also
present.
Direct support for the idea that genes held in this ‘bivalent’
state are susceptible to methylation was provided by analyses
of individual clones of stem cells containing ectopically over-
expressed BMI1 (BMI1 is a central component of PRC1 involved in
recognition of the H3K27me3 mark, established by EZH2, and has
a role in subsequent maintenance of PcG-mediated long-term gene
silencing). Clones of stem cells were identified that exhibited
increased methylation of the Wnt antagonist gene SFRP5, and
where the pattern of histone methylation had changed to resemble
more closely that found in cancer cells.
Schlesinger et al (2007) demonstrated that genes methylated in
cancer cells are specifically packaged with nucleosomes containing
H3K27me3. This chromatin mark is established on unmethylated
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CpG island genes early in development and then maintained in
differentiated cell types by the presence of an EZH2-containing
P complex. In cancer cells, the presence of this complex brings
about the recruitment of DNA methyltransferases, leading to
de novo methylation (Figure 1). These results also suggested that
the tumour-specific targeting of de novo methylation is pre-
programmed by an established epigenetic system that normally
has a role in marking embryonic genes for repression.
AN EPIGENETIC LINK TO CANCER AETIOLOGY
It is thought that lifestyle and environmental or dietary exposure
may contribute to cancer risk through epigenetic mechanisms.
Although little data relate directly to prostate cancer, examination
of other systems provides strong evidence that the occurrence of
epigenetic changes is age related. Ageing is associated with global
hypomethylation together with hypermethylation of specific genes,
in the same way as in cancer. Inactivation of specific genes by DNA
methylation in the ageing colonic mucosa has been proposed to be
one of the earliest events in the development of cancer at this site
(Issa et al, 1994). Analysis of monozygotic (identical) twins
demonstrate that they are epigenetically indistinguishable in early
life. However with ageing, differences in DNA methylation
patterns, histone modification and gene expression pattern are
observed. These differences were most pronounced when the twins
had lived apart, suggesting a role for diet and environment (Fraga
et al, 2005b). SirT1 and IGF signalling, both linked to epigenetic
mechanisms, have each been implicated in controlling the ageing
process.
A variety of dietary and environmental factors have been linked
to epigenetic changes: these include smoking, alcohol consump-
tion, drinking green tea, dietary selenium levels, folate and
methionine deficiencies, and the presence of resversatrol and
dihydrocoumarins; high selenium consumption is known to be
associated with lower risk of developing prostate cancer.
Resversatrol (a molecule present in several plants including purple
grapes) and dihydrocoumarins (found in sweet clover) inhibit
SirT1. Prostate cancer frequently progresses very slowly, and for
many cases, treatments that delay the development or progression
of this disease, even marginally, could have a significant clinical
impact. If epigenetic alterations occur gradually through ageing or
under the influence of dietary factors as the first step in cancer
development, they may provide an excellent target for preventative
strategies. In this respect, it is worthy of note that the potential
chemopreventive agents sulphoraphane, butyrate, and diallyl
disulphide are all known to act as inhibitors of HDACs. The
antioxidant EGCG, present in green tea, is a DNMT inhibitor.
Support for the idea that chemoprevention strategies can be
successful comes from the study of patients with genetically
determined hyperhomocysteinemia where treatment by folate
supplementation can restore the normal DNA methylation and
expression patterns of specific genes (Ingrosso et al, 2003).
Epigenetic marks may not always be erased by passage through
the germ line, and in some cases can be inherited from one
generation to the next. The influence of maternal diet in this
process is well documented. It is, however, now emerging that
paternal transmission may also occur. This has been described in
mice for the Axin(Fu) allele, and epidemiological evidence
(Pembrey et al, 2006) supports the view that epigenetic effects of
smoking can be inherited thorough father-to-son transmission.
The general failure to identify gene mutations that account for
genetic inheritance in prostate cancer suggests that it may be
appropriate to examine epigenetic mechanism of inheritance. The
identification of such genes represents a significant technical
challenge, although technologies for the genome-wide screening of
DNA-methylation patterns and histone marks that would be
required for target gene identification are starting to become
available (see below).
GENOME-WIDE ANALYSIS OF EPIGENETIC
PATTERNS
Whole genome analysis of histone modifications and of proteins






























Recruitment of DMNT via EZH2
Figure 1 Working model for transition of bivalent stem cell chromatin to inactive chromatin during cancer development. In stem cells, chromatin exists in
a bivalent state characterised by the absence of DNA methylation and the presence of both activating (e.g., H3K4me2) and inactivating (H3K27me3)
markers. During cancer development, it is proposed that recruitment of DMNTs through EZH2 causes methylation of DNA. The inactive chromatin is
characterised by the markers H3K9me2, H3K9me3, and H3K27me3. Model taken from the data presented by Ohm et al (2007) and Schlesinger et al
(2007).
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ChiP-based approaches (Zhao et al, 2007; Roh and Zhao, 2008).
For example, Zhao et al (2007) used ChiP coupled to a sequencing
strategy to explore H3Kme3 and H3K27me3 landscapes in human
ES cells. A variety of strategies involving high-throughput DNA
sequencing or hybridisation to oligonucleotide micorarray may be
used for the genome-wide analysis of DNA methylation pattern
(reviewed by Zilberman and Henikoff, 2007). For example,
Schumacher et al (2006) analysed enriched unmethylated DNA
from human brain or Affymerix tiling arrays for chromosomes 21
and 22 and found, as expected, that most unmethylated sites were
close to the 50-end of genes. Using SNP arrays at 50 k and 250 k
resolution (Kerkel et al, 2008) has demonstrated that genome-wide
approaches can be used also to identify allele-specific methylation.
The specific applications of these technologies to prostate cancer
represent an important area of future investigation.
EPIGENETICS AND CANCER THERAPY
Enzymes controlling epigenetic status and involved in cross talk
between epigenetic systems are potential targets for cancer
therapy. The enzymes include HDACs, HATs, co-activators
including TIP60, PcG proteins including EZH2, and the DNMTs.
In principle, enzymes that modulate the activities of these proteins
are also potential drug targets, as are proteins that bind methylated
CpG sequences. One strategy would be to try to use inhibitors of
these proteins to reprogramme cells returning their epigenetic
status to that reminiscent of a normal cell. A complication with
this targeting strategy is that the effects of each individual targeted
protein are most likely to be complex and difficult to predict.
Several HDAC inhibitors have activity in the nanomolar range and
have been demonstrated to inhibit growth of prostate cancer.
Clinical trials have, however, been largely restricted to cancer types
other than prostate (Gallinari et al, 2007). Such drugs may have
relevance to cancers containing the TMPRSS2 :ERG fusion where
HDAC1 is overexpressed (Iljin et al, 2006). In this respect,
romidepsin, a bicyclic depsipeptide HDAC inhibitor, has a disease
control rate of 14% when used to treat patients with hormone
refractory disease (Parker et al, 2007).The ability of 5-azacytidine
and other nucleoside analogues to inhibit DNMTs, cause
hypomethylation and alter gene transcription in cultured prostate
cancer cells is well documented, but only limited clinical trials have
been performed.
CONCLUSION
Epigenetics is now accepted as mainstream area of cancer research.
However, many challenges remain both in understanding its
importance in cancer development and in applying new knowledge
to the benefit of prostate cancer patients. There is an urgent need
to comprehensively assess epigenetic alterations on a genomic
scale in a broad variety of normal cells, stem cells, and in
corresponding cancer cells and to assess the importance of the role
of small RNAs and their therapeutic potential.
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